Australian biotech market watch 09/10/09
Friday, 09 October, 2009
The All Ordinaries has shed some of the gains made over the past couple of days to level out around 4,753 as of 1pm this afternoon.
However, the S&P/ASX 200 Health Care index has underperformed the rest of the market, dropping 176 points to 8,428.
A large portion of that drop can be attributed to a 2.5% fall in CSL (ASX:CSL) to $31.89, closely followed by Primary Health Care (ASX:PRY), which also shed 2.5%, down to $6.34, as well as Cochlear (ASX:COH), which lost $1.42, or 2.1%, to $64.84.
Ansell (ASX:ANN), which has had a good run this week, plateaued around $10.59, down 15c from yesterday's close.
Ramsay Health Care (ASX:RHC) saw an early rally, but has since dropped back 8c below yesterday's close to sit at $10.64.
On the up side, ResMed (ASX:RMD) experienced a 1.8% lift to $5.06, and Blackmores (ASX:BKL) hit a 12 month high of $21.27.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
